Hope for MSA patients: continued access to experimental drug ATH434
NCT ID NCT07531433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers ongoing access to the experimental drug ATH434 for people with multiple system atrophy (MSA) who completed a prior Phase 2 study. Participants take the drug twice daily by mouth. The goal is to allow continued treatment for those who may benefit, as judged by their doctor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can an experimental pill slow a rare brain disease? a trial puts ATH434 to the test.
- Can a new rowing seat help veterans with paralysis row freely?
- Scientists decode gait signatures to spot brain diseases
- Can a Thigh-Worn sensor outsmart dizziness questionnaires?
- Scientists hunt for clues to diagnose Parkinson's earlier